This clinical trial is focused on the long-term follow-up of patients who have been treated with a type of therapy known as CAR T-cell therapy. This therapy involves using a patient’s own immune cells, called T-cells, which are modified to better recognize and attack cancer cells. The study includes patients who have received this treatment for various conditions, using products developed by Novartis or Penn. The main purpose of the study is to observe and describe any delayed side effects that might be related to the previous CAR T-cell therapy.
The study involves several treatments, including PHE885, YTB323, and Tisagenlecleucel. These treatments are given as a dispersion for infusion, which means they are administered directly into the bloodstream through an intravenous infusion. PHE885 uses a patient’s own T-cells that are engineered to target a specific protein on cancer cells called the B cell maturation antigen. YTB323 involves T-cells that are modified to target another protein known as CD19. Tisagenlecleucel is also a type of CAR T-cell therapy that targets cancer cells using a similar approach.
Throughout the study, researchers will monitor patients for any new health issues that may arise after receiving CAR T-cell therapy. This includes checking for new cancers, serious infections, neurological disorders, autoimmune conditions, and blood disorders. The study will also track the presence of the modified T-cells in the blood over time and observe any changes in the patient’s health status, such as relapse or progression of their condition. The study aims to provide valuable information on the long-term safety and effects of CAR T-cell therapy.



Austria
Belgium
Denmark
Finland
France
Germany
Greece
Italy
Norway
Spain
Sweden
The Netherlands